The collaboration specifically aims to improve cell-based ion-channel assays in screening applications, Cellectricon said.
Financial terms of the alliance were not disclosed.
This isn't the first time the companies have crossed paths. Last June, AstraZeneca installed several of Cellectricon's DynaFlow ion channels screening platforms worldwide.
Cell-Based Assay News, a GenomeWeb News sister publication, reported in June 2004 that AstraZeneca had decided to use DynaFlow in its ion channel drug-discovery program. Cellectricon said today that AstraZeneca has placed multiple orders for DynaFlow systems since that time.
DynaFlow is based on a computer-controlled microfluidic chip, and is designed to be used with any cell, patch-clamp configuration, active substance, and ion channel, Cellectricon said.